We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ortho Exhibits High Quality, Accurate and Cost Effective COVID19 Testing Solutions at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021

Ortho Clinical Diagnostics (Raritan, NJ, USA) exhibited its range of high quality, accurate and cost effective COVID19 testing solutions at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo held at the Georgia World Congress Center in Atlanta, September 26-30.

Over the span of the four day event, attendees connected with global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory medicine.


Illustration
Illustration

Ortho has been at the forefront of developing high quality, accurate, cost effective COVID19 testing solutions that run at high volumes. At AACC 2021, Ortho demonstrated its high-throughput testing solutions for SARS-CoV-2 infection, antibody detection and antigen detection. These included the high-throughput, highly accurate VITROS SARS-CoV-2 antigen test that detects acute infection of SARS-CoV-2. The test delivers fast, high-volume testing for active infection with excellent specificity and sensitivity, making it a viable alternative to PCR testing.

In addition, Ortho highlighted its three qualitative antibody tests, including the VITROS COVID-19 Total and IgG antibody assays that provide highly accurate and reliable detection of SARS-CoV-2 antibodies to help clinicians and researchers understand immune response; and its VITROS Anti-SARS-CoV-2 Total N antibody test that is designed to capture total antibodies to the nucleocapsid protein. Also on display at AACC 2021 was the VITROS Anti-SARS-CoV-2 IgG quantitative test that helps labs to quantify the level of COVID-19 antibodies for patients and individuals in their communities. The VITROS Anti-SARS-CoV-2 IgG quantitative test is the first quantitative test to receive U.S. Food and Drug Administration (FDA) EUA. Ortho also demonstrated its VITROS Performance Dashboard that allows labs to view productivity data from Ortho analyzers including: test volumes, positivity rates, quality and efficiency information to help make more informed decisions for the hospital and community.

Related Links:
Ortho Clinical Diagnostics 


New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
Automated Blood Typing System
IH-500 NEXT
New
Silver Member
Oncology Molecular Diagnostic Test
BCR-ABL Dx ELITe MGB Kit
New
Histamine ELISA
Histamine ELISA

Latest AACC 2021 News

Study Showing Differing COVID-19 Antibody Profiles Among Vaccinated and Naturally Infected Individuals Presented at AACC 2021

Study Reveals Varying Antibody Responses and Adverse Reactions Among Recipients of Different COVID-19 Vaccines

Novel Study on Performance of Coronavirus Tests in Children Presented at 2021 AACC Annual Scientific Meeting